Virax BiolabsVRAX
VRAX
About: Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
Employees: 17
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
40% more funds holding
Funds holding: 5 [Q3] → 7 (+2) [Q4]
3.58% less ownership
Funds ownership: 5.03% [Q3] → 1.45% (-3.58%) [Q4]
67% less capital invested
Capital invested by funds: $424K [Q3] → $141K (-$282K) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$3
202%
upside
Avg. target
$3
202%
upside
High target
$3
202%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Yi Chen 27% 1-year accuracy 46 / 173 met price target | 202%upside $3 | Buy Initiated | 31 Mar 2025 |
Financial journalist opinion
Positive
Benzinga
2 weeks ago
Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating
H.C. Wainwright initiated coverage on Virax Biolabs Group Limited VRAX, a U.K.-based company focused on detecting immune responses and diagnosing viral diseases.
Neutral
PRNewsWire
1 month ago
Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes
LONDON , March 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today that it has started enrolling patients into its United Kingdom based, multi-center clinical study (NCT06731179). Conducted in collaboration with the United Kingdom's National Health Service, investigators aim to assess the ViraxImmune™ FluoroSpot T cell assay performance in detecting T cell dysfunction in post-acute infection syndrome patients, including those with long COVID, post-treatment Lyme disease (PTLD), and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
Neutral
PRNewsWire
1 month ago
Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting
LONDON , March 13, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced it has presented data evaluating the role of T-Cell dysfunction in post-acute infection syndromes (PAIS) at the World Immune Regulation Meeting (WIRM) in Davos, Switzerland. PAISs are often associated with a dysfunction of the immune system, notably progressive T-Cell exhaustion.
Neutral
PRNewsWire
1 month ago
Virax Biolabs to Present at 19th World Immune Regulation Meeting
LONDON , March 5, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that the company's management will present at the 19th World Immune Regulation Meeting (WIRM), which will take place March 12-15, 2025, in Davos, Switzerland. Presentation Details: Title: Evaluation of T cell dysfunction in post acute infection syndromes Presenter: Dr. Nigel McCracken, Chief Operating Officer at Virax Biolabs Date: Wednesday, March 12, 2025, at 20:00 Location: Foyer A1, The Congress Center, Davos, Switzerland Additionally, the Company will be showcasing its portfolio of immune profiling products for research use at Booth 116, and management will be available for discussions with research organizations and potential customers.
Neutral
PRNewsWire
1 month ago
Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy
Company Positioned to Support Public Health through Vaccine Efficacy Testing and Data-Driven Insights into Patients' Immune Profiles to Empower Informed Decisions on Vaccination LONDON , Feb. 25, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") believes that its technology aligns with the United States Department of Health and Human Services' commitment to prioritizing transparency on vaccine efficacy. This initiative is essential for empowering the public with the information needed to make informed health decisions.
Neutral
Accesswire
2 months ago
Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait
CHICAGO, IL / ACCESS Newswire / January 23, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into a supplemental exclusive distribution agreement with Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax") to distribute Virax-branded Avian Influenza Virus Real-Time PCR Kits across all remaining Gulf Cooperation Council (GCC) countries, including Saudi Arabia, the United Arab Emirates (UAE), Qatar, and Kuwait. The previous exclusive distribution agreement, announced on January 13, 2025, was limited to Oman and Bahrain.
Neutral
Accesswire
3 months ago
Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries
CHICAGO, IL / ACCESSWIRE / January 13, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into a distribution agreement with Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax") to distribute Virax-branded Avian Influenza Virus ("AIV") Real-Time PCR Kits across various major European markets and certain Gulf Cooperation Council (GCC) countries. Specifically, Cosmos Health gains exclusive rights to distribute these kits in Greece and Cyprus, as well as non-exclusive rights in select European countries, including France, Portugal, Spain, The Netherlands, Belgium, Sweden, Finland, Denmark, Norway, Germany, Switzerland, and Austria.
Neutral
PRNewsWire
4 months ago
Virax Biolabs' CEO James Foster Issues Letter to Shareholders
LONDON , Dec. 17, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases, today announced that Mr. James Foster, Chief Executive Officer of Virax, has issued a letter to shareholders outlining the Company's plans for 2025 and highlights recent accomplishments.
Neutral
PRNewsWire
4 months ago
Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland
LONDON , Dec. 10, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into a non-exclusive distribution agreement with French company Tebubio to expand the distribution of its ImmuneSelect Research Use portfolio into countries in the European Union, as well as in Norway and Switzerland. "We are honored to announce this agreement with Tebubio, who will prove to be instrumental in increasing the accessibility of ImmuneSelect for life science institutions across a crucial market such as Europe," said James Foster, CEO of Virax Biolabs.
Neutral
PRNewsWire
5 months ago
Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland
LONDON , Oct. 23, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into a distribution agreement with Europa Biosite to commercialize the company's ImmuneSelect Research Use portfolio in the United Kingdom and Ireland through its wholly owned subsidiary Cambridge Bioscience. "ImmuneSelect is an important suite of profiling solutions for assessing adaptive immunity and we are pleased to partner with Europa Biosite, a leader in life science distribution across Europe," said James Foster, CEO of Virax Biolabs.
Charts implemented using Lightweight Charts™